Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: Efficacy and safety of targeted agents, such as everolimus and sunitinib, have been demonstrated in the prospective trials for patients with GEP-NET. Considering heterogeneous clinical features of NET, evaluation of real-world outcomes with these agents are necessary. We retrospectively analyze the treatment outcomes of everolimus and sunitinib for patients (pts) with GEP-NET.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
